BankChampaign National Association Takes Position in Genmab A/S Sponsored ADR $GMAB

BankChampaign National Association purchased a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the first quarter, HoldingsChannel reports. The fund purchased 25,622 shares of the company’s stock, valued at approximately $687,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC lifted its stake in shares of Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 616 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. V Square Quantitative Management LLC bought a new position in shares of Genmab A/S during the 1st quarter valued at approximately $34,000. NewEdge Advisors LLC raised its holdings in Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after buying an additional 1,143 shares during the period. Finally, Brown Brothers Harriman & Co. raised its holdings in Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after buying an additional 780 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. Truist Financial initiated coverage on shares of Genmab A/S in a research note on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target for the company. New Street Research set a $43.00 price target on shares of Genmab A/S in a report on Wednesday, July 22nd. Finally, Weiss Ratings raised shares of Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $39.28.

Genmab A/S Stock Up 0.4%

NASDAQ:GMAB opened at $28.64 on Friday. The company has a market cap of $17.86 billion, a price-to-earnings ratio of 21.70, a price-to-earnings-growth ratio of 1.79 and a beta of 0.84. Genmab A/S Sponsored ADR has a twelve month low of $21.00 and a twelve month high of $35.43. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The stock has a fifty day simple moving average of $26.99 and a 200-day simple moving average of $28.16.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.